問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Endocrinology

Division of General Internal Medicine

更新時間：2023-09-19

莊立民CHUANG, LEE-MING
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊立民

List

36Cases

2010-03-03 - 2010-12-14

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2006-05-01 - 2007-06-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-05-23 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-07-19 - 2018-06-25

Phase III

PIONEER 6 – Cardiovascular outcomes. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Oral Semaglutide

Participate Sites
4Sites

Terminated4Sites

2015-11-26 - 2022-12-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

  • Condition/Disease

    Diabetic kidney disease

  • Test Drug

    BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯
Taipei Medical University Hospital

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2015-09-01 - 2017-04-04

Phase III

A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 Diabetes Mellitus (EASE2)

  • Condition/Disease

    Type 1 Diabetes Mellitus

  • Test Drug

    Jardiance®

Participate Sites
8Sites

Terminated7Sites

陳清助
China Medical University Hospital-Taipei

未分科

2012-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-09-01 - 2009-09-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2009-03-01 - 2011-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-09-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB